Mineralys Therapeutics, Inc. Common Stock (MLYS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Mineralys Therapeutics, Inc. Common Stock (MLYS) has a cash flow conversion efficiency ratio of -0.062x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-39.47 Million) by net assets ($638.14 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Mineralys Therapeutics, Inc. Common Stoc's balance sheet to measure how much of total assets are equity-financed.
Mineralys Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Mineralys Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore MLYS long-term investment intensity to see how much of total assets are deployed in long-term investments.
Mineralys Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mineralys Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
89bio Inc
NASDAQ:ETNB
|
-0.192x |
|
SL Science Holding Limited Ordinary Shares
NASDAQ:SLBT
|
N/A |
|
Mach Natural Resources LP
NYSE:MNR
|
0.054x |
|
Torunlar Gayrimenkul Yatirim Ortakligi AS
IS:TRGYO
|
-0.002x |
|
Hilltop Holdings Inc
NYSE:HTH
|
0.123x |
|
Custom Truck One Source Inc
NYSE:CTOS
|
0.030x |
|
Zai Lab Ltd
NASDAQ:ZLAB
|
-0.018x |
|
Energi Mega Persada Tbk
JK:ENRG
|
0.094x |
Annual Cash Flow Conversion Efficiency for Mineralys Therapeutics, Inc. Common Stock (2020–2025)
The table below shows the annual cash flow conversion efficiency of Mineralys Therapeutics, Inc. Common Stock from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Mineralys Therapeutics, Inc. Common Stoc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $646.69 Million | $-142.42 Million | -0.220x | +74.68% |
| 2024-12-31 | $191.26 Million | $-166.31 Million | -0.870x | -158.34% |
| 2023-12-31 | $241.15 Million | $-81.17 Million | -0.337x | -160.21% |
| 2022-12-31 | $-52.27 Million | $-29.22 Million | 0.559x | -11.97% |
| 2021-12-31 | $-22.93 Million | $-14.56 Million | 0.635x | -7.25% |
| 2020-12-31 | $-3.60 Million | $-2.46 Million | 0.685x | -- |
About Mineralys Therapeutics, Inc. Common Stock
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, an… Read more